| 51 |
21247791 | Geranylgeraniol - a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw. | 2011 Mar |
1 |
| 52 |
21335425 | Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate. | 2011 May |
2 |
| 53 |
21420384 | Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells. | 2011 Apr 22 |
2 |
| 54 |
21465521 | Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy. | 2011 May |
1 |
| 55 |
21497677 | The relationship between the chemistry and biological activity of the bisphosphonates. | 2011 Jul |
2 |
| 56 |
21555003 | Bisphosphonates: the first 40 years. | 2011 Jul |
4 |
| 57 |
21702715 | Farnesyl pyrophosphate synthase modulators: a patent review (2006 - 2010). | 2011 Sep |
2 |
| 58 |
22091898 | Bisphosphonates and osteonecrosis of the jaw. | 2011 Dec |
1 |
| 59 |
19819230 | Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. | 2010 Mar 1 |
1 |
| 60 |
20191015 | Genetic polymorphism of geranylgeranyl diphosphate synthase (GGSP1) predicts bone density response to bisphosphonate therapy in Korean women. | 2010 Mar |
2 |
| 61 |
20299227 | Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). | 2010 Apr 1 |
1 |
| 62 |
20450493 | Sterol-regulatory-element-binding protein 2 and nuclear factor Y control human farnesyl diphosphate synthase expression and affect cell proliferation in hepatoblastoma cells. | 2010 Jul 15 |
1 |
| 63 |
20533067 | Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. | 2010 Nov |
1 |
| 64 |
20539033 | Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. | 2010 Jun |
1 |
| 65 |
20544107 | Discovery of potent inhibitor for farnesyl pyrophosphate synthase in the mevalonate pathway. | 2010 Aug 7 |
2 |
| 66 |
20711197 | Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. | 2010 Sep |
2 |
| 67 |
20722616 | Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. | 2010 |
2 |
| 68 |
20801032 | Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase. | 2010 Oct 1 |
3 |
| 69 |
20832326 | Synthesis and biological evaluation of a series of aromatic bisphosphonates. | 2010 Oct 15 |
1 |
| 70 |
19016713 | Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. | 2009 Jan |
1 |
| 71 |
19233551 | Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. | 2009 Jun 8 |
1 |
| 72 |
19309137 | Lipophilic bisphosphonates as dual farnesyl/geranylgeranyl diphosphate synthase inhibitors: an X-ray and NMR investigation. | 2009 Apr 15 |
2 |
| 73 |
19371349 | Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. | 2009 Jun |
1 |
| 74 |
19665949 | Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. | 2009 Oct 1 |
1 |
| 75 |
19699819 | The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. | 2009 Dec |
2 |
| 76 |
19810397 | Bisphosphonates and osteonecrosis of the jaw--current thoughts. | 2009 Sep |
1 |
| 77 |
18214569 | Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. | 2008 Jun |
2 |
| 78 |
18327899 | Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. | 2008 Apr 10 |
1 |
| 79 |
18442135 | Structures of a potent phenylalkyl bisphosphonate inhibitor bound to farnesyl and geranylgeranyl diphosphate synthases. | 2008 Nov 1 |
2 |
| 80 |
18454049 | Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. | 2008 Apr |
1 |
| 81 |
18463892 | Rab proteins and Rab-associated proteins: major actors in the mechanism of protein-trafficking disorders. | 2008 Jul |
1 |
| 82 |
18473904 | Structural analysis of farnesyl pyrophosphate synthase from parasitic protozoa, a potential chemotherapeutic target. | 2008 Mar |
2 |
| 83 |
18800762 | Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. | 2008 Sep 25 |
1 |
| 84 |
16996129 | Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. | 2007 Mar |
1 |
| 85 |
17277961 | [Introduction to bisphosphonates. History and functional mechanisms]. | 2007 Feb |
1 |
| 86 |
17291279 | Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. | 2007 Feb |
1 |
| 87 |
17535895 | Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. | 2007 Jun 12 |
2 |
| 88 |
17959891 | Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. | 2007 Nov |
1 |
| 89 |
18056045 | Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. | 2007 Nov |
2 |
| 90 |
22460750 | Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders. | 2007 Jan |
1 |
| 91 |
16216433 | Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy. | 2006 |
1 |
| 92 |
16650801 | Recent advances in understanding the mechanism of action of bisphosphonates. | 2006 Jun |
1 |
| 93 |
16684881 | The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. | 2006 May 16 |
2 |
| 94 |
16831938 | Bisphosphonates: from bench to bedside. | 2006 Apr |
4 |
| 95 |
16892359 | Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. | 2006 Feb |
4 |
| 96 |
16932286 | Drug insight: Bisphosphonates for postmenopausal osteoporosis. | 2006 Apr |
1 |
| 97 |
16956297 | Investigation of the catalytic mechanism of farnesyl pyrophosphate synthase by computer simulation. | 2006 Sep 14 |
2 |
| 98 |
17062705 | Molecular mechanisms of action of bisphosphonates: current status. | 2006 Oct 15 |
2 |
| 99 |
17090032 | Solid-state NMR, crystallographic, and computational investigation of bisphosphonates and farnesyl diphosphate synthase-bisphosphonate complexes. | 2006 Nov 15 |
2 |
| 100 |
15828834 | Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption. | 2005 Apr 21 |
2 |